Loading…
DOCOSANOL is a brand name for Docosanol. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Treatment of early stages (prodrome or erythema phase) of recurrent labial herpes simplex infection (cold sores) in immunocompetent patients.
Verbatim from this product's MHRA label. Tap a section to expand.
Route of Administration:
Cutaneous use Posology Adults and adolescents (12-18 years): Apply a thin film carefully over the entire cold sore 5 times a day (approximately every 3 hours during waking hours). Treatment must begin as soon as possible after the first cold sore symptoms or signs appear (pain, burning/itching/tingling or redness) as efficacy has not been demonstrated when the treatment is initiated at the stage of an already developed blister or ulcer.
Treatment should continue until healing has occurred, usually 4 to 6 days, or for a maximum of 10 days.
Elderly:
No special dose recommendation. ).
Dosage in renal failure:
No dose adjustments necessary due to negligible topical absorption
Very common (≥1/10) Common (≥1/100 to <1/10) Uncommon (≥1,000 to <1/100) Rare (≥1/10,000 to <1/1,000) Very rare (<1/10,000) Not known (cannot be estimated from the available data). Results from clinical trials of the treatment of recurrent labial herpes simplex demonstrate no difference in the frequency or type of undesirable effects in patients treated with Docosanol 10% Cream or placebo.
7% of placebo- treated patients). 3% of placebo-treated patients). Facial oedema has also been reported but these application site adverse reactions are consistent with normal facial reactions experienced with cold sores. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.
Avoid application close to or in the eyes. This formulation contains propylene glycol and may cause skin irritation. The cream should not be used in immunocompromised patients. Treatment with the cream should not be initiated at the stage of an already developed blister or ulcer.
Paediatric population There is no treatment experience available for the use in children below the age of 12 years and only limited experience in adolescent (aged 12-18 years). It is recommended that the cream should not be used in children under 12 years.
Hypersensitivity to the active substance "docosanol" or to any of the excipients.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Docosanol in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.